Loading...
Loading...
FGEN| Name | Value |
|---|---|
| Revenues | 40.1M |
| Cost of Revenue | 4.2M |
| Gross Profit | 35.9M |
| Operating Expense | 86.8M |
| Operating I/L | -63.5M |
| Other Income/Expense | -0.7M |
| Interest Income | 4.3M |
| Pretax | -64.2M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -63.6M |
FibroGen, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutics for serious unmet medical needs. The company's primary revenue-generating products include Roxadustat, an oral small molecule inhibitor for the treatment of anemia in chronic kidney disease, and Pamrevlumab, a human monoclonal antibody in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy. FibroGen, Inc. also has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
